Rushed Innovation: Evidence from Drug Licensing

We study the drug licensing behavior (acquisition of rights for developing drugs) of large pharmaceutical firms in the aftermath of large negative shocks to their pipelines, phase 3 failures (P3Fs)...

[1]  P. Danzon,et al.  Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances , 2003, Journal of health economics.

[2]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[3]  George P. Ball,et al.  Recalls, Innovation, and Competitor Response: Evidence from Medical Device Firms , 2018 .

[4]  K. Śmietana,et al.  Trends in clinical success rates , 2016, Nature Reviews Drug Discovery.

[5]  R. Merges,et al.  The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry , 2003 .

[6]  Craig Nelson,et al.  The key to successful collaborations: Rigorous and independent due diligence , 1969 .

[7]  A. Jones.  Minimizing leakage of value from R&D alliances , 2007, Nature Reviews Drug Discovery.

[8]  A. Arora,et al.  The Market for Technology , 2010 .

[9]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[10]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[11]  Michael Goodman.  Market watch: Sales of biologics to show robust growth through to 2013 , 2009, Nature Reviews Drug Discovery.

[12]  P. Dubois,et al.  Market Size and Pharmaceutical Innovation , 2011 .

[13]  B. Freidlin,et al.  Data monitoring committees and interim monitoring guidelines. , 1999, Controlled clinical trials.

[14]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[15]  K. B. Hendricks,et al.  Delays in new product introductions and the market value of the firm: the consequences of being late to the market , 1997 .

[16]  Karl T. Ulrich,et al.  Valuing R&D Projects in a Portfolio: Evidence from the Pharmaceutical Industry , 2007, Manag. Sci..

[17]  Ashish Arora,et al.  A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development , 2009, Manag. Sci..

[18]  I. Cockburn,et al.  The changing structure of the pharmaceutical industry. , 2004, Health affairs.

[19]  M. Ceccagnoli,et al.  How Reliable Is the Market for Technology? , 2018, Review of Economics and Statistics.

[20]  Anurag Sharma,et al.  Linking Product Development Outcomes to Market Valuation of the Firm: The Case of the U.S. Pharmaceutical Industry* , 2004 .

[21]  Dominique M. Hanssens,et al.  Marketing and Firm Value: Metrics, Methods, Findings, and Future Directions , 2008 .

[22]  Stefan Wager,et al.  Estimation and Inference of Heterogeneous Treatment Effects using Random Forests , 2015, Journal of the American Statistical Association.

[23]  B. Bayus.  Speed‐to‐Market and New Product Performance Trade‐offs , 1997 .

[24]  Robert Kneller,et al.  The importance of new companies for drug discovery: origins of a decade of new drugs , 2010, Nature Reviews Drug Discovery.

[25]  I. Cockburn,et al.  Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. , 2001, Journal of health economics.

[26]  Nicos Savva,et al.  The economics of licensing contracts. , 2008, Nature biotechnology.

[27]  Xuelin Li,et al.  Find and Replace: R&D Investment Following the Erosion of Existing Products , 2018, Manag. Sci..

[28]  Scott Stern,et al.  Is There a Market for Ideas? , 2009 .

[29]  Bo Wang,et al.  Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. , 2016, JAMA internal medicine.

[30]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[31]  D. Mowery,et al.  Technological overlap and interfirm cooperation: implications for the resource-based view of the firm , 1998 .

[32]  Gary P. Pisano,et al.  R&D Performance, Collaborative Arrangements and the Market for Know-How: A Test of the "Lemons" Hypothesis in Biotechnology , 1997 .

[33]  B. Hamilton,et al.  Learning, Private Information, and the Economic Evaluation of Randomized Experiments , 2003, Journal of Political Economy.

[34]  Gary P. Pisano,et al.  Science Business: The Promise, the Reality, and the Future of Biotech , 2006 .

[35]  J. Birkinshaw,et al.  Management innovation , 2005, IEEE Engineering Management Review.

[36]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[37]  Daron Acemoglu,et al.  Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry , 2003 .

[38]  J. Arrowsmith.  Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.

[39]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[40]  James Mittra,et al.  Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms , 2007, Technol. Anal. Strateg. Manag..

[41]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[42]  D. Teece.  Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .

[43]  D.,et al.  Regression Models and Life-Tables , 2022 .

[44]  Manuel Hermosilla,et al.  Market Size and Innovation: The Intermediary Role of Technology Licensing , 2018, Research Policy.

[45]  Teck-Hua Ho,et al.  New product development: the performance and time-to-market tradeoff , 1996 .

[46]  I. Cockburn,et al.  Scale, scope, and spillovers: the determinants of research productivity in drug discovery. , 1996, The Rand journal of economics.

[47]  G. Imbens,et al.  Large Sample Properties of Matching Estimators for Average Treatment Effects , 2004 .

[48]  David O. Meltzer,et al.  Do Important Drugs Reach the Market Sooner , 1994 .

[49]  Jehoshua Eliashberg,et al.  New Product Announcement Signals and Incumbent Reactions , 1995 .

[50]  Rosa M. Abrantes-Metz,et al.  Pharmaceutical Development Phases: A Duration Analysis , 2004 .

[51]  R. W. Hansen,et al.  Journal of Health Economics , 2022 .

[52]  The impact of new product introductions on the market value of firms , 1993 .

[53]  N. Rajagopalan,et al.  Are all ‘sharks’ dangerous? new biotechnology ventures and partner selection in R&D alliances , 2012 .

[54]  Rajesh K. Chandy,et al.  From Invention to Innovation: Conversion Ability in Product Development , 2006 .

[55]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[56]  Jack A. Nickerson,et al.  Strategic Management of R&D Pipelines with Cospecialized Investments and Technology Markets , 2007, Manag. Sci..

[57]  David H. Hsu,et al.  When Does Start-Up Innovation Spur the Gale of Creative Destruction? , 2000 .

[58]  Walter W. Powell,et al.  Inter-Organizational Collaboration in the Biotechnology Industry , 1996 .

[59]  Matthew J. Higgins,et al.  The outsourcing of R&D through acquisitions in the pharmaceutical industry , 2006 .

[60]  D. Rubin,et al.  Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score , 1985 .

[61]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[62]  S. Athey,et al.  Generalized random forests , 2016, The Annals of Statistics.

[63]  A. Arora,et al.  Markets for Technology: The Economics of Innovation and Corporate Strategy , 2004 .

[64]  Christine Moorman,et al.  The Convergence of Planning and Execution: Improvisation in New Product Development , 1998 .

[65]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.

[66]  Manuel Hermosilla,et al.  Therapeutic Translation of Genomic Science: Opportunities and Limitations of Gwas , 2017 .

[67]  P. Danzon,et al.  Mergers and Acquisitions in the Pharmaceutical and Biotech Industries , 2004 .

[68]  Josh Lerner,et al.  Contractibility and the Design of Research Agreements , 2004 .

[69]  Chi Heem Wong,et al.  Estimation of clinical trial success rates and related parameters , 2018, Biostatistics.

[70]  Pharmaceutical Profits and the Social Value of Innovation , 2014 .